Uterine Cancer Therapeutics & Diagnostics

Uterine Cancer Therapeutics & Diagnostics

Global Uterine Cancer Therapeutics and Diagnostics Market to Reach $24.3 Billion by 2027

In the changed post COVID-19 business landscape, the global market for Uterine Cancer Therapeutics and Diagnostics estimated at US$18.4 Billion in the year 2020, is projected to reach a revised size of US$24.3 Billion by 2027, growing at aCAGR of 4.1% over the period 2020-2027. Endometrial Carcinomas, one of the segments analyzed in the report, is projected to record 5% CAGR and reach US$16 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Uterine Sarcomas segment is readjusted to a revised 2.5% CAGR for the next 7-year period.

The U.S. Market is Estimated at $5.1 Billion, While China is Forecast to Grow at 7.6% CAGR

The Uterine Cancer Therapeutics and Diagnostics market in the U.S. is estimated at US$5.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$5 Billion by the year 2027 trailing a CAGR of 7.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.5% and 4.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Select Competitors (Total 46 Featured) -

  • Abbott Laboratories, Inc.
  • ARIAD Pharmaceuticals, Inc.
  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi SA
  • Siemens Healthineers
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Uterine Cancer Therapeutics & Diagnostics – Global Key Competitors Percentage Market Share in 2020 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2020 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
TABLE 2: World Historic Review for Uterine Cancer Therapeutics & Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 3: World 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2019 & 2027
TABLE 4: World Recent Past, Current & Future Analysis for Uterine Sarcomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
TABLE 5: World Historic Review for Uterine Sarcomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 6: World 15-Year Perspective for Uterine Sarcomas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2019 & 2027
TABLE 7: World Recent Past, Current & Future Analysis for Endometrial Carcinomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
TABLE 8: World Historic Review for Endometrial Carcinomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 9: World 15-Year Perspective for Endometrial Carcinomas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2019 & 2027
TABLE 10: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
TABLE 11: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 12: World 15-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2019 & 2027
TABLE 13: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
TABLE 14: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 15: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2019 & 2027
TABLE 16: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
TABLE 17: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 18: World 15-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2019 & 2027
TABLE 19: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
TABLE 20: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 21: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2019 & 2027
TABLE 22: World Recent Past, Current & Future Analysis for Follow-Up Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
TABLE 23: World Historic Review for Follow-Up Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 24: World 15-Year Perspective for Follow-Up Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2019 & 2027
TABLE 25: World Recent Past, Current & Future Analysis for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
TABLE 26: World Historic Review for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 27: World 15-Year Perspective for Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2019 & 2027
TABLE 28: World Recent Past, Current & Future Analysis for Pelvic Ultrasound by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
TABLE 29: World Historic Review for Pelvic Ultrasound by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 30: World 15-Year Perspective for Pelvic Ultrasound by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2019 & 2027
TABLE 31: World Recent Past, Current & Future Analysis for Hysteroscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
TABLE 32: World Historic Review for Hysteroscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 33: World 15-Year Perspective for Hysteroscopy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2019 & 2027
TABLE 34: World Recent Past, Current & Future Analysis for Dilation and Curettage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
TABLE 35: World Historic Review for Dilation and Curettage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 36: World 15-Year Perspective for Dilation and Curettage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2019 & 2027
TABLE 37: World Recent Past, Current & Future Analysis for CT scan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
TABLE 38: World Historic Review for CT scan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 39: World 15-Year Perspective for CT scan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2019 & 2027
TABLE 40: World Uterine Cancer Therapeutics & Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027
III. MARKET ANALYSIS
UNITED STATES
Uterine Cancer Therapeutics & Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2020 (E)
TABLE 41: USA Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 42: USA Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 43: USA 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 44: USA Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 45: USA Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 46: USA 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 47: USA Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 48: USA Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 49: USA 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
CANADA
TABLE 50: Canada Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 51: Canada Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 52: Canada 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 53: Canada Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 54: Canada Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 55: Canada 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 56: Canada Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 57: Canada Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 58: Canada 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
JAPAN
Uterine Cancer Therapeutics & Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2020 (E)
TABLE 59: Japan Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 60: Japan Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 61: Japan 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 62: Japan Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 63: Japan Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 64: Japan 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 65: Japan Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 66: Japan Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 67: Japan 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
CHINA
Uterine Cancer Therapeutics & Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2020 (E)
TABLE 68: China Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 69: China Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 70: China 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 71: China Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 72: China Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 73: China 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 74: China Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 75: China Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 76: China 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
EUROPE
Uterine Cancer Therapeutics & Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2020 (E)
TABLE 77: Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
TABLE 78: Europe Historic Review for Uterine Cancer Therapeutics & Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 79: Europe 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2019 & 2027
TABLE 80: Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 81: Europe Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 82: Europe 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 83: Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 84: Europe Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 85: Europe 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 86: Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 87: Europe Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 88: Europe 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
FRANCE
Uterine Cancer Therapeutics & Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2020 (E)
TABLE 89: France Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 90: France Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 91: France 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 92: France Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 93: France Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 94: France 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 95: France Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 96: France Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 97: France 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
GERMANY
Uterine Cancer Therapeutics & Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2020 (E)
TABLE 98: Germany Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 99: Germany Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 100: Germany 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 101: Germany Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 102: Germany Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 103: Germany 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 104: Germany Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 105: Germany Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 106: Germany 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
ITALY
TABLE 107: Italy Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 108: Italy Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 109: Italy 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 110: Italy Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 111: Italy Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 112: Italy 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 113: Italy Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 114: Italy Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 115: Italy 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
UNITED KINGDOM
Uterine Cancer Therapeutics & Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2020 (E)
TABLE 116: UK Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 117: UK Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 118: UK 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 119: UK Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 120: UK Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 121: UK 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 122: UK Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 123: UK Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 124: UK 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
SPAIN
TABLE 125: Spain Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 126: Spain Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 127: Spain 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 128: Spain Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 129: Spain Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 130: Spain 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 131: Spain Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 132: Spain Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 133: Spain 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
RUSSIA
TABLE 134: Russia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 135: Russia Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 136: Russia 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 137: Russia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 138: Russia Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 139: Russia 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 140: Russia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 141: Russia Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 142: Russia 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
REST OF EUROPE
TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 144: Rest of Europe Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 145: Rest of Europe 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 147: Rest of Europe Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 148: Rest of Europe 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 150: Rest of Europe Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 151: Rest of Europe 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
ASIA-PACIFIC
Uterine Cancer Therapeutics & Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2020 (E)
TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
TABLE 153: Asia-Pacific Historic Review for Uterine Cancer Therapeutics & Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 154: Asia-Pacific 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2019 & 2027
TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 156: Asia-Pacific Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 157: Asia-Pacific 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 159: Asia-Pacific Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 160: Asia-Pacific 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 162: Asia-Pacific Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 163: Asia-Pacific 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
AUSTRALIA
Uterine Cancer Therapeutics & Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2020 (E)
TABLE 164: Australia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 165: Australia Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 166: Australia 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 167: Australia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 168: Australia Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 169: Australia 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 170: Australia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 171: Australia Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 172: Australia 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
INDIA
Uterine Cancer Therapeutics & Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2020 (E)
TABLE 173: India Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 174: India Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 175: India 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 176: India Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 177: India Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 178: India 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 179: India Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 180: India Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 181: India 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
SOUTH KOREA
TABLE 182: South Korea Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 183: South Korea Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 184: South Korea 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 185: South Korea Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 186: South Korea Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 187: South Korea 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 188: South Korea Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 189: South Korea Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 190: South Korea 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
REST OF ASIA-PACIFIC
TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 192: Rest of Asia-Pacific Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 195: Rest of Asia-Pacific Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 198: Rest of Asia-Pacific Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
LATIN AMERICA
Uterine Cancer Therapeutics & Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2020 (E)
TABLE 200: Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
TABLE 201: Latin America Historic Review for Uterine Cancer Therapeutics & Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 202: Latin America 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2019 & 2027
TABLE 203: Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 204: Latin America Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 205: Latin America 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 206: Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 207: Latin America Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 208: Latin America 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 209: Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 210: Latin America Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 211: Latin America 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
ARGENTINA
TABLE 212: Argentina Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 213: Argentina Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 214: Argentina 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 215: Argentina Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 216: Argentina Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 217: Argentina 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 218: Argentina Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 219: Argentina Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 220: Argentina 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
BRAZIL
TABLE 221: Brazil Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 222: Brazil Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 223: Brazil 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 224: Brazil Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 225: Brazil Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 226: Brazil 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 227: Brazil Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 228: Brazil Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 229: Brazil 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
MEXICO
TABLE 230: Mexico Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 231: Mexico Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 232: Mexico 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 233: Mexico Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 234: Mexico Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 235: Mexico 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 236: Mexico Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 237: Mexico Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 238: Mexico 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
REST OF LATIN AMERICA
TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 240: Rest of Latin America Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 241: Rest of Latin America 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 243: Rest of Latin America Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 244: Rest of Latin America 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 246: Rest of Latin America Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 247: Rest of Latin America 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
MIDDLE EAST
Uterine Cancer Therapeutics & Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2020 (E)
TABLE 248: Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
TABLE 249: Middle East Historic Review for Uterine Cancer Therapeutics & Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 250: Middle East 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2019 & 2027
TABLE 251: Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 252: Middle East Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 253: Middle East 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 254: Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 255: Middle East Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 256: Middle East 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 257: Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 258: Middle East Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 259: Middle East 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
IRAN
TABLE 260: Iran Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 261: Iran Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 262: Iran 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 263: Iran Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 264: Iran Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 265: Iran 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 266: Iran Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 267: Iran Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 268: Iran 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
ISRAEL
TABLE 269: Israel Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 270: Israel Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 271: Israel 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 272: Israel Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 273: Israel Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 274: Israel 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 275: Israel Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 276: Israel Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 277: Israel 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
SAUDI ARABIA
TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 279: Saudi Arabia Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 280: Saudi Arabia 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 282: Saudi Arabia Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 283: Saudi Arabia 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 285: Saudi Arabia Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 286: Saudi Arabia 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
UNITED ARAB EMIRATES
TABLE 287: UAE Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 288: UAE Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 289: UAE 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 290: UAE Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 291: UAE Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 292: UAE 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 293: UAE Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 294: UAE Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 295: UAE 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
REST OF MIDDLE EAST
TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 297: Rest of Middle East Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 298: Rest of Middle East 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 300: Rest of Middle East Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 301: Rest of Middle East 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 303: Rest of Middle East Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 304: Rest of Middle East 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
AFRICA
Uterine Cancer Therapeutics & Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2020 (E)
TABLE 305: Africa Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 306: Africa Historic Review for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial Carcinomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 307: Africa 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Uterine Sarcomas and Endometrial Carcinomas for the Years 2012, 2019 & 2027
TABLE 308: Africa Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 309: Africa Historic Review for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 310: Africa 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Therapeutics - Percentage Breakdown of Value Sales for Surgery, Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up Treatment for the Years 2012, 2019 & 2027
TABLE 311: Africa Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
TABLE 312: Africa Historic Review for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
TABLE 313: Africa 15-Year Perspective for Uterine Cancer Therapeutics & Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan for the Years 2012, 2019 & 2027
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings